Name: Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003
SKU: KLI959630
Availability: InStock

Description

The hard-fought battle over Medicare’s prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts.

This market briefing from Kalorama describes and assesses the provisions of the “Medicare Prescription Drug, Improvement and Modernization Act of 2003” and predicts their potential impacts on the American pharmaceutical industry. Numerous tables and figures regarding the Medicare age population, it economics and healthcare expenditures, support conclusions regarding this controversial piece of legislation.

EXECUTIVE SUMMARY

BACKGROUND

DEMOGRAPHICS OF THE OLDER POPULATION

Figure 1: Actual and Projected Population of Individuals Aged 65 Years and Older in the United States: 1900 – 2050

Figure 2: Actual and Projected Percentage of the United States Population Age 65 and Older: 1900 – 2050

Table 1: Life Expectancy by Age Group and Sex, in Years 1900 – 2000

Figure 3: Actual and Projected Percentage of the United States Population Age 85 and Older: 1900 – 2050

Table 2: Marital Status of the United States Population Age 65 and Older by Age Group and Sex: 2002

ECONOMIC STATUS OF THE OLDER POPULATION

Figure 4: Income Distribution of the United States Population Age 65 and Over 1974 – 2001

Figure 5: Percentage of the United States Population Living in Poverty by Age Group 65 Years of Age and Older: 1982 – 2001

Table 3: Median Household Net Worth By Age Group in the United States for Individuals 65 Years of Age and Older: 1984 – 1999

Figure 6: Household Income Distribution in the United States by Age Group got Individuals 65 Years of Age and Older: 2000

PRESCRIPTION DRUG EXPENDITURES AMONG THE OLDER POPULATION

Table 4: Average Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older, in 1999 Dollars, by Age Group: 1992 – 1999

Figure 7: Distribution of Medicare Expenditures by Age Group 1992 and 1999

Figure 8: The Ratio of Average Healthcare Expenditures by Age Group to the Average Healthcare Expenditures for the Group of Individuals 65 Years of Age and Older as a Whole 1992 – 1999

Table 5: Percentage of Healthcare Expenditures Incurred by Medicare Beneficiaries Age 65 or Older by Level of Expenditures: 1999

Table 6: Distribution of Healthcare Expenditures Among Medicare Beneficiaries Age 65 and Older by Institutional Status: 1999

Table 7: Components of Healthcare Expenditures: 1992 and 1999

Table 8: Percentage Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Age Group: 1999

Table 9: Dollar Value Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Age Group: 1999

Figure 9: Trending in the Percentage Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Age Group: 1999

Figure 10: Trending in the Dollar Value Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Age Group: 1999

Table 10: Percentage Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Income Level: 1999

Figure 11: Trending in the Percentage Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Income Level: 19993

Table 11: Dollar Value Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Income Level: 1999

Figure 12: Trending in the Dollar Value Distribution of Major Components of Healthcare Expenditures Among Medicare Beneficiaries Age 65 or Older by Income Level: 1999

PROVISIONS OF THE NEW MEDICARE PHARMACEUTICAL BENEFITS

Table 12: Timeline for Medicare Changes, 2004 to 2007

ANALYSIS AND CONCLUSIONS

Table 14: Provisions of the Kennedy/Dingell Bill to Amend the Medicare Prescription Drug, Improvement and Modernization Act of 2003 Submitted as the “Defense of Medicare and Real Medicare Prescription Drug Benefit Act”
Table 15: Estimated Beneficiary Savings Under the New Medicare Prescription Drug Benefit by Prescription Costs in Each Beneficiary Category
Table 16: Estimated Average Beneficiary Savings Under the New Medicare Prescription Drug Benefit by Age Group In Each Beneficiary Category
Table 17: Estimated Average Beneficiary Savings Under the New Medicare Prescription Drug Benefit by Income Group
Figure 13: Average Annual Prescription Drug Use by Age Group: 1999

Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003

Description

Table of Contents

Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline